Here's why the Telix (ASX:TLX) share price is leaping higher today

Telix shares are on the move…

| More on:
Two happy scientists analysing test results in a lab

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Telix shares up 9.88% to $4.56 
  • The company's bone marrow conditioning treatment, TLX66 received Orphan Drug Designation (ODD) status from the United States Food and Drug Administration (FDA) 
  • Being granted ODD enables Telix to receive special benefits of achieving incentivised targets for TLX66 

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is heading north during late morning trade following a company announcement.

At the time of writing, the biotechnology company's shares are selling for $4.56 apiece, up 9.88%.

What did Telix announce?

Investors are pushing Telix shares higher after investors digest the company's latest announcement to the ASX.

According to its release, Telix advised it has been granted Orphan Drug Designation (ODD) from the United States Food and Drug Administration (FDA) for its bone marrow conditioning treatment, TLX66.

Bone marrow conditioning is performed prior to hematopoietic stem cell transplantation (HSCT).

The latter is a procedure where a patient's healthy stem cells are collected from blood or bone marrow before treatment. The stem cells are then safely stored, and given back to the patient after treatment.

The Orphan Drug Act was created by the FDA to motivate biopharmaceutical companies in developing potential medicines for rare or 'orphan' diseases. The ODD provides preferential treatment that enhances a company's standing with the agency.

HSCT is being used increasingly in malignant hematological conditions, such as multiple myeloma and acute myeloid leukemia, and in non-hematological malignancies and rare/immune-mediated diseases.

In 2018, more than 22,700 HSCTs were performed in the United States.

The welcomed decision enables the company to receive special benefits of achieving incentivised targets. This includes eligibility for seven years of market exclusivity after FDA approval, discounted tax credits of 50% of drug testing costs, additional protocol assistance, reduced review times and specific marketing authorisation application fees waived.

Telix chief medical officer, Dr Colin Hayward added:

The granting of an Orphan Drug Designation by the FDA for TLX66, combined with recent encouraging data from prior studies in hematological malignancies and autoimmune disease provides a strong impetus to advance our development plans for TLX66.

This treatment has potential application in a number of hematological cancers and rare diseases and potentially also in the future for conditioning for cell and gene therapies.

Telix share price summary

It's been a challenging couple of months for Telix shareholders, with the company's share price down 42% in 2022.

However, when looking at the past 12 months, the company's shares are hovering around 2% higher.

On valuation grounds, Telix presides a market capitalisation of roughly $1.4 billion.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »